Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HealoTEAR is a proprietary fluid-gel formulation technology developed by Healome Therapeutics, a spinout from the University of Birmingham. The technology utilizes a novel material that flows like a liquid upon application but self-structures into a thin, clear, protective layer on the ocular surface. This layer is designed to provide enhanced drug retention, lubrication, and protection for 2 to 8 hours before being cleared by blinking. The platform is preservative-free and can be used as a carrier to deliver various therapeutics. Healome Therapeutics is applying this technology to reformulate existing glaucoma medications to improve their residence time and therapeutic efficacy on the eye surface, potentially enhancing patient compliance and outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on HealoTEAR (Glaucoma reformulation).